Amira Pharmaceuticals, Inc.

Panmira Pharmaceuticals, LLC

Merck Sharp + Dohme Corp.

Bristol-myers Squibb Compnay

Merck + Co., Inc.

California Institute of Technology

Yale University

Orion Ophthalmology LLC

Pipeline Therapeutics, Inc.

Inception 3, Inc.

Brickell Biotech, Inc.

Thomas Jon Seiders

Jeannie M Arruda

John Howard Hutchinson

Jeffrey Roger Roppe

Bowei Wang

Brian Andrew Stearns

Deborah Volkots

Nicholas Simon Stock

Lucy Xiumin Zhao

Yen Truong

Jill Melissa Scott

Ryan Christopher Clark

Timothy Andrew Parr

Nicholas D Smith

Dehua Huang

Nicholas David Cosford

Jean-Michel Andre Vernier

Joseph E Payne

Brian Walter Eastman

Heather Renee Coate

Steve Fong Poon

Xiumin Zhao

Chris King

Yiwei Li

David Nathan Zalatan

Catherine Yuling Lee

Robert H Grubbs

Lida R Tehrani

Austin Chih-Yu Chen

Victor W Rosso

David J Donnelly

Renata Marcella Oballa

Jason Edward Brittain

David Andrew Powell

Robert Gomez

Samuel J Bonacorsi, Jr

Christopher David King

Tao Sheng

Steven D Goldberg

Joonyoung Kim

Adrienne Pena

Tritin Tran

Richard E Carson

Nabeel Nabulsi

Yiyun Huang

Yem Pham Truong

Wang Bowei

Donald W Ward

Kai Cao

Jean-Dominique Gallezot

Yen Pham Truong

Nicholas D Cosford

Timothy Parr

The present disclosure provides crystalline Compound I and crystalline Compound II, pharmaceutical compositions comprising one of said crystalline compounds suitable for intratympanic administration, and methods for treating otic disorders using the crystalline compounds and the pharmaceutical compositions.

Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders

This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition. 

Aliphatic prolinamide derivatives

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Polycyclic compounds as lysophosphatidic acid receptor antagonists

The present invention relates to radiolabeled LPA1 receptor antagonists or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of LPA1 receptors in mammals.

Radioligands for imaging the LPA-1 receptor

Compounds as lysophosphatidic acid receptor antagonists

Described herein is the LPA1 antagonist 1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.

Polycyclic LPA1 antagonist and uses thereof

Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis

Described herein are ophthalmic pharmaceutical compositions, wherein the ophthalmic pharmaceutical compositions are in a form suitable for administration to an eye of a mammal. Ophthalmic pharmaceutical compositions disclosed herein include at least one DPreceptor antagonist compound and are used to treat or prevent ophthalmic diseases or conditions.

Ophthalmic pharmaceutical compositions of DP2 receptor antagonists

The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.

Thiazolyl mGluR5 antagonists and methods for their use

Lysophosphatidic acid receptor antagonists

Growing community of inventors

San Diego, CA, United States of America

Thomas Jon Seiders